JIANMIN GROUP(SH:600976)2024-09-30 10:47Sales Performance - The pharmaceutical industrial sector experienced a decline in sales output compared to the same period last year due to a shift in assessment models from dispatch assessment to pure sales assessment [1] - OTC product line sales increased by 57% compared to the same period last year, with significant marketing efforts for products like Bian Tong capsules [1] - The sales output of Bian Tong capsules has shown a positive growth trend, supported by strategic partnerships with key chain pharmacies [2] Product Development - The prescription drug product line maintained a positive development trend, with slight sales increases for products like Bian Tong capsules and Xiao Er Bao Tai Kang granules [2] - The company has over 40 pediatric products, including the newly approved pediatric innovative drug, Xiao Er Zi Bei Xuan Fei syrup [2] - The company is focusing on the development of pediatric drugs, with more than half of the 25 new drug projects currently in research being pediatric products [2] Marketing Strategy - The company will continue to invest in advertising while maintaining a strategic approach to advertising scale and market targeting [2] - The dual-brand strategy around "Long Mu" and "Jian Min" will be emphasized to enhance brand strength and product sales [2] Future Development Plans - The company aims to refine marketing management and enhance digital marketing capabilities, focusing on high-quality health products and services [3] - There is a commitment to continue the development of innovative traditional Chinese medicine and pediatric drugs, with plans to explore mergers and acquisitions for product enhancement [3] - The company will accelerate production line upgrades and invest in smart manufacturing to strengthen sustainable development capabilities [3]